“…Despite the technical soundness and effectiveness in treating aortic arch pathologies, hybrid TEVAR carries a relatively high risk of post-operative complications (endoleaks, stroke, spinal cord ischemia, e.g.). The standard treatment for these complications remains controversial [ 2 , [4] , [5] , [6] ].…”